The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.

Karadag-Saygi, NAİME; Akyuz, GÜLSEREN; Bizargity, Peyman; Ay, NADİYE

doi:10.3109/09513590.2011.579657

The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.

Karadag-Saygi E., Akyuz G., Bizargity P., Ay P.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, vol.27, no.12, pp.1033-6, 2011 (SCI-Expanded)

Publication Type: Article / Article
Volume: 27 Issue: 12
Publication Date: 2011
Doi Number: 10.3109/09513590.2011.579657
Journal Name: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1033-6
Keywords: Osteoporosis, risedronate, osteoprotegerin, bone marker, SOLUBLE RECEPTOR ACTIVATOR, FACTOR-KAPPA-B, DISEASE-ACTIVITY, MINERAL DENSITY, PAGETS-DISEASE, LIGAND, TURNOVER, FRACTURES, THERAPY, MASS
Marmara University Affiliated: Yes

Abstract

Background. To evaluate the effect of risedronate treatment on osteoprotegerin (OPG), C-terminal cross-linking telopeptide of type 1 collagen (CTX), osteocalcin (OC), and deoxypyridinoline (DPD).